Promotion of Drugs and Medical Devices for Unapproved Uses: Hearing Before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, First Session, June 11, 1991, Volume 4
United States, United States. Congress. House. Committee on Government Operations. Human Resources and Intergovernmental Relations Subcommittee
U.S. Government Printing Office, 1992 - 395 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
action activities addition adverse advertising agency American application approved associated authors believe cause Center Chairman clinical Collagen Corporation concerns considered consumers continue correct cosmetic defects Department Dermatology develop device discussed disease Drug Administration editors effects event expenses incurred exposure facial FDA's files Food and Drug further Health Honorarium human implants increase indicate injectable collagen injectable silicone interest involved issues Journal labeling letter liquid silicone manufacturer material meeting Michigan months occur patients percent period physicians PM/DM possible practice present problems promotion questions reaction reason received records regarding regulation Reimbursement Reimbursement for expenses request response Retin-A risk safety scars scientific severe skin specific statement subjects submitted Symposium tissue Topical treated treatment University Weiss wrinkles
Page 109 - Authorship All persons designated as authors should qualify for authorship. Each author should have participated sufficiently in the work to take public responsibility for the content.
Page 154 - DEPARTMENT OF HEALTH AND HUMAN SERVICES BEFORE THE SUBCOMMITTEE ON HUMAN RESOURCES AND INTERGOVERNMENTAL RELATIONS COMMITTEE ON GOVERNMENT OPERATIONS US HOUSE OF REPRESENTATIVES JUNE 4, 1992 FOR RELEASE ONLY UPON DELIVERY Good Morning Mr.
Page 123 - The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial.
Page 74 - Pharmacopeia, or any supplement to them, (2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals...
Page 153 - We appreciate your continued interest in these issues, and I will be happy to answer questions. [The prepared statement of Hon.
Page 111 - Pharmacology, except as described in an attachment. Furthermore, I attest that I shall produce the data on which the manuscript is based for examination by the editors or their assignees should they request it.
Page 113 - Owners and editors of medical journals have a common endeavor - the publication of a reliable and readable journal, produced with due respect for the stated aims of the journal and for costs. The functions of owners and editors, however, are different. Owners have the right to appoint and dismiss editors and to make important business decisions in which editors should be involved to the fullest extent possible. Editors must have full authority for determining the editorial content of the journal....
Page 6 - The gentleman from New Jersey, Mr. Payne. Mr. PAYNE. Thank you very much, Mr. Chairman.
Page 111 - I certify that any affiliations with or involvement (either competitive or amiable) in any organization or entity with a direct financial interest in the subject matter or materials discussed in the manuscript (eg employment, consultancies, stock ownership, honoraria, expert testimony, etc.) are noted below.